eResearchTechnology (ERES)

[Vipyr]

eResearch Technology (ERES) shares have been on a downward trend since the company decided not to bring its previously announced share offering to market—due to lackluster share prices.

Investors punished the company by taking its shares down further, but they are missing out on a fabulous growth story. Its spring acquisition of CareFusion stands to increase its sales more than 50% this year and 30% next year, translating into greater earnings on the bottom line.

But the acquisition isn't the only story with ERES. It is continuing its internal growth with a launch of a comprehensive suite of electronic patient-reported outcome (ePRO) solutions. According to the company, its solutions include "the VIAPhone, VIAPad, VIAPen and VIAWeb, all of which offer the advantages of simplicity, mobility and immediacy of use over traditional paper based methods."

Throughout the recession, ERES continued to pump out new products, hone its balance sheet and look for profitable growth arenas. The shares are trading at a very discounted level; you may purchase them on any pullbacks below $6, with a first target of $15